Nisa Investment Advisors
ORIC icon

Nisa Investment Advisors’s Oric Pharmaceuticals ORIC Stock Holding History

Nisa Investment Advisors’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.5K Sell
2,536
-774
-23% -$7.02K ﹤0.01% 2094
2026
Q1 		$41.9K Buy
3,310
+900
+37% +$10.2K ﹤0.01% 1741
2025
Q4 		$19.7K Sell
2,410
-26
-1% -$299 ﹤0.01% 1946
2025
Q3 		$29.2K Hold
2,436
– – ﹤0.01% 1826
2025
Q2 		$24.7K Buy
2,436
+2,422
+17,300% +$16.3K ﹤0.01% 1844
2025
Q1 		$78 Sell
14
-198
-93% -$1.73K ﹤0.01% 2971
2024
Q4 		$1.71K Buy
212
+71
+50% +$651 ﹤0.01% 2538
2024
Q3 		$1.45K Buy
141
+73
+107% +$722 ﹤0.01% 2489
2024
Q2 		$481 Buy
68
+34
+100% +$304 ﹤0.01% 2696
2024
Q1 		$468 Buy
+34
New +$404 ﹤0.01% 2507
2022
Q2 		– Sell
-16,100
Closed -$86K – 2473
2022
Q1 		$86K Buy
+16,100
New +$145K ﹤0.01% 1674
2021
Q4 		– Sell
-3,350
Closed -$70K – 2300
2021
Q3 		$70K Hold
3,350
– – ﹤0.01% 1844
2021
Q2 		$59K Buy
+3,350
New +$73.4K ﹤0.01% 1891

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Nisa Investment Advisors's ORIC Position: Q2 2026 in Review

Nisa Investment Advisors reduced its Oric Pharmaceuticals (ORIC) stake by 23% in Q2 2026, selling an estimated $7.02K and leaving 2,536 shares worth $27.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2094.

Nisa Investment Advisors first reported a position in ORIC in Q2 2021 and has held it in 13 quarters since. The position peaked at $86K in Q1 2022. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Nisa Investment Advisors held 2,536 shares of Oric Pharmaceuticals worth $27.5K as of Q2 2026.
  • Nisa Investment Advisors sold 774 Oric Pharmaceuticals shares in Q2 2026, an estimated $7.02K.
  • Oric Pharmaceuticals made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2094 holding.
  • Nisa Investment Advisors first reported a position in Oric Pharmaceuticals in Q2 2021 and has held it in 13 quarters since.
  • Nisa Investment Advisors's Oric Pharmaceuticals position peaked at $86K in Q1 2022.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.